Abstract: The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.

Abstract: The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.

Abstract: A dietary supplement for legume protein containing galactosidase, methionine, medium chain fatty acids or their derivatives, and optionally thermogenic additives, antioxidants, vitamins and spices. Improved legume protein is also provided, wherein the dietary supplement is already admixed with the legume protein. It may be formulated as a dried powder that can easily be reconstituted as refried beans, protein shakes, soups and the like. Alternatively, ready-to-eat foods may be prepared as described. A method of reducing body weight is also provided, the method being consuming at least a single serving of legume protein per day, wherein said legume protein is as described above. Methods of weight control, include avoiding the consumption of foods with a high glycemic index and consuming foods with a low glycemic index and also avoiding the consumption of foods that stimulate the appetite and consuming foods that satiate the appetite.

Abstract: A dietary supplement for legume protein containing galactosidase, methionine, medium chain fatty acids or their derivatives, and optionally thermogenic additives, antioxidants, vitamins and spices. Improved legume protein is also provided, wherein the dietary supplement is already admixed with the legume protein. It may be formulated as a dried powder that can easily be reconstituted as refried beans, protein shakes, soups and the like. Alternatively, ready-to-eat foods may be prepared as described. A method of reducing body weight is also provided, the method being consuming at least a single serving of legume protein per day, wherein said legume protein is as described above. Methods of weight control, include avoiding the consumption of foods with a high glycemic index and consuming foods with a low glycemic index and also avoiding the consumption of foods that stimulate the appetite and consuming foods that satiate the appetite.

Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.

Abstract: Protein and peptide free compositions are described, which are useful in treating endotoxemia. The compositions contain a phospholipid and a neutral lipid, preferably phosphatidylcholine and triglyceride.

Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.

Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.

Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering a lipid into which the endotoxin of concern is associated, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconstituted particle, although this is by no means required.

Abstract: A reconstituted high density lipoprotein containing particle is disclosed. The particle is useful in removing excess lipid soluble material from a subject to which it is administered, as well as in delivery of lipid soluble pharmaceuticals to subjects or patients.

Abstract: A communication system is provided in which one data transmitting display terminal has the capability of transmitting a data stream in coded form to at least one data receiving terminal over a communication linkage. This data transmitting terminal further includes the capability of displaying, when necessary, the stream of coded data directly on its display so that if there is a transmission problem, the coded data itself can be analyzed in diagnosing the problem.The present communications system has the further capability of diagnosing data streams at remote display terminals. For example, if one transmitting terminal is communicating with a receiving terminal and a problem arises between the two terminals, the system provides the capability of the transmitting terminal sending the data stream to another receiving terminal remote from the first two terminals.

Abstract: A communication adapter circuit (10) is connected to a processor through a data bus (12)and a control bus (14). Data and control signals are provided through the buses (12,14) to a timer circuit (18), a programmable peripheral interface circuit (20), an asynchronous and bisynchronous control circuit (22) and an SDLC/HDLC control circuit (24). Each of the control circuits (22, 24) includes parallel-to-serial and serial-to-parallel conversion circuitry. A clock select circuit (32) operates in conjunction with the timer circuit (18) and the programmable peripheral interface circuit (20) to establish a data transmission rate for the data flow through the adapter circuit (10). From the control circuits (22, 24) the data is transmitted through a bi-directional serial line (44) to a dual modem switch (56). From the switch (56) the data is transmitted to either an EIA interface circuit (60) to a conventional modem or through a line (64) to an internal modem.

Abstract: A communication adapter circuit (10) is connected to a processor through processor I/O interface buses (12, 14). Data and control signals are provided through the buses (12, 14) to a timer circuit (18), a programmable peripheral interface circuit (20), an asynchronous and bisynchronous control circuit (22) and an SDLC/HDLC control circuit (24). Each of the control circuits (22, 24) includes parallel-to-serial and serial-to-parallel conversion circuitry. A clock select circuit (32) operates in conjunction with the timer circuit (18) and the programmable peripheral interface circuit (20) to establish a data transmission rate for the data flow through the adapter circuit (10). From the control circuits (22, 24) the data is transmitted through a modem interface bus (44) to a dual modem switch (56). From the switch (56) the data is transmitted to either an EIA RS 232 interface circuit (60) to a conventional modem or through a bus (64) to an internal modem.

Abstract: Dialkyl esters of 5-carbo[etiocholane-3'.alpha.-7'.alpha., 12'.alpha.-trihydroxy-17'.beta.(1" methyl-4' butyl]oxy-4-hydroxy-4-methylpentyl-1-phosphonate and 5-carbohexadecyloxy-4-hydroxy-4-methylpentyl-1-phosphonate are shown to inhibit cholesterol biosynthesis in rat liver cells. Preparation of the active compounds is given.